



## **SUNSHINE HOLDINGS PLC**

CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE QUARTER ENDED 31st March 2024

## **GROUP CHIEF EXECUTIVE OFFICER'S MESSAGE**

#### Dear Shareholder.

During the reporting period, domestic macroeconomic stability was significantly restored, which had a positive impact on economic activity. As a result, Sunshine Holdings PLC (SUN) recorded a consolidated revenue of LKR 55.5 billion for the year ended 31st March 2024 (FY24), representing a 7.0% year-on-year growth. The Group revenue, from Healthcare, Consumer brands and Agribusiness sectors, contributed 50.0%, 34.8% and 15.0%, respectively.

In FY24, the gross profit margin reached 31.0%, marking a significant improvement of 500 basis points compared to the previous year. The gross profit increased by LKR 3.7 billion, representing a robust 27.6% year-on-year growth, primarily driven by the margin expansion in both the healthcare and consumer segments explained in detail below. Amidst the increasing strain on operating expenses, the Group's operating profit (EBIT) for the year closed at LKR 8.7 billion, experiencing a growth of 23.7% YoY (year on year). The reduction in deferred tax, which lowered the effective tax rate from 36.1% to 25.4%, positively impacted the profit after tax (PAT). As a result, the Group recorded a PAT of LKR 6.0 billion for FY24, compared to LKR 3.6 billion reported in the previous year. Additionally, the finance cost for the same period totaled LKR 1.2 billion, including interest on lease liabilities (LKR 127 million) and an exchange loss of (LKR 188 million), as opposed to LKR 1.5 billion in the previous year. This reduction supported by the current favorable movement of interest rate during the year.

Profit attributable to equity shareholders (PATMI) closed at LKR 4.5 billion for FY24, an increase of 97.5% YoY.

#### **Financial Snapshot**

i manda onapone	•			
	4QFY24	Vs 4QFY23	FY24	Vs FY 23
Healthcare	6,736	7.2%	27,773	16.1%
Consumer	4,492	-8.7%	19,324	1.6%
Agri	1,838	-13.3%	8,321	-5.1%
Other	82	n/m	116	-37.0%
Revenue	13,148	-1.3%	55,534	7.0%
Gross Profit	3,630	9.3%	17,240	27.6%
GP Margin	27.6%	2.7%	31.0%	5.0%
EBIT	1,268	7.5%	8,662	23.7%
EBIT Margin	9.6%	0.8%	15.6%	2.1%
Net Finance Cost	(307)	-14.4%	(591)	-40.1%
Income Tax Expense	(391)	-53.3%	(2,053)	0.4%
PAT	570	n/m	6,019	66.4%

#### Healthcare

Healthcare sector revenue for FY24 grew 16.1% YoY (year on year), driven by the topline improvement in the Medical Devices Division (SMD) and Pharma manufacturing business.

Improvement in EBIT Margin in the Healthcare sector is owing to the higher contribution of medical devices, pharmaceutical manufacturing business and retail pharmacy business, driven higher capacity utilization and exchange rate movement during the period.

Despite the constraints posed by consumer purchasing power throughout the year, the pharmaceutical segment's revenue remained stable, primarily driven by the recovery of volume in the latter part of the year. The medical devices segment on the other hand grew 28.1% YOY driven primarily by price and volume increases in the government sector.

Healthguard Pharmacy, the retail segment witnessed a 19.2% YoY increase, driven by both value and volume improvements and a gross margin improvement driven by the favorable topline impact of the business.

Lina - the pharmaceutical manufacturing business, experienced revenue growth of 137.4% YoY (year on year), driven by the increase in the capacity utilization of

the Metered Dose Inhaler (MDI) plant. Lina was able to supply most of the MDI requirements of the Medical Supplies Division of the Government for 2023.

#### **Consumer Goods**

The Consumer brands sector, which includes both export and domestic businesses, reported revenue of LKR 19.3 billion in FY24, a marginal increase of 1.6% YoY.

Given the significant Rupee appreciation against the USD (US dollar), lower tea prices and volume reduction in certain export markets resulted in a 22.5% YoY decline in revenue for the Export business.

Despite the VAT (Value Added Tax) impact on 4Q FY24, the domestic consumer brands business had an impressive performance for FY24, driven by increased volumes in the tea segment, despite a volume contraction in confectionary, resulting in a revenue growth of 19.0% YoY in FY24.

Our Tea brands Zesta, Watawala Thei and Ran Kahata remained resilient despite challenging consumer sentiment. The tea category experienced a volume growth of 10.0% YoY in FY24 and a value growth of 37.6% YoY. The confectionery segment revenue contracted by 7.1% YoY, despite an increase in selling price, due to a volume contraction of 25.7% YoY.

EBIT margin which stood at 27.5% in FY24, showed a significant improvement compared to 17.9% the previous year, primarily driven by the exceptional performance of the domestic tea segment because of the decline in tea costs, and scale benefits from volume growth.

PAT from the Consumer sector grew over due to the growth in the domestic tea business and finance cost savings, which was partially offset by the adverse impact from the export business.

#### **Agribusiness**

The Agribusiness sector reported a revenue of LKR 8.3 billion in FY24, a 5.1% YoY decline. This was due to the contraction in revenue of the palm oil business (down 9.3% YoY). The top line of the segment was impacted by the downward trend in palm oil prices. Palm oil production increased by 15.2% YoY to 15.7 million Kgs in FY24 cf. 13.7 million Kgs last year. The decrease in fertilizer costs compared to last year has enabled the sector to partially mitigate the impact of price reductions. PAT for the period amounted to LKR 2.4 billion, an increase of 2.9% YoY. Despite the increase in operating expenses, the PAT margin improved due to the reduction in impairment of investment in subsidiaries and decrease in tax expenses.

The Dairy business revenue grew by 29.7% YoY due to increases in both production volume and milk prices. The turnaround led to a reduction in the net loss of the dairy segment recorded to LKR 139.2 million during FY24 cf. net loss of LKR 320.9 million in FY23.

#### Outlook

We have recently announced the proposed equity investment of up to LKR 3,270 million by the International Finance Corporation (IFC) into Sunshine Healthcare Lanka (SHL). Subject to satisfaction of conditions, IFC will own approximately 14.7% stake in SHL. With IFC's support, we are poised to scale up SHL's operations significantly, from expanding our manufacturing with Lina to enhancing our diagnostic capabilities, distribution network, and retail presence. This is the second investment by IFC into our group, previously lending us LKR 1,020 million in 2021 to fund Sunshine Consumer's acquisition of Daintee. We are honored to partner with the International Finance Corporation and these investments underscores the confidence in Sunshine Holdings' potential to deliver on our growth plans.

Despite positive signs in the broader macro economy, the average consumer's

disposable income remains constrained due to various adjustments in direct and indirect taxes, as well as inflationary pressures. The Group remains confident in its ability to navigate challenges and sustain resilience in the upcoming quarters while being committed to maintaining a consumer-centric approach, ensuring that meeting the ever-evolving needs of consumers remains integral to our strategic vision.

In Healthcare we are closely monitoring the changes in the exchange rate, which is sensitive to our margins. The Healthcare Sector will prioritize ensuring accessible and high-quality healthcare services. We will place strong emphasis on both organic and inorganic growth within our core focus areas to capitalize on opportunities in the healthcare space.

The Consumer sector will continue to face challenges owing to macroeconomic pressures on consumer purchasing power. While the export business remains a key focus area for the group, we will continue to invest behind our consumer brands and drive distribution synergies in the retail channels to maintain our high market share.

In the Agribusiness sector, we expect palm oil prices to remain stable in the near term, in line with global pricing, while crop volumes are expected to gradually increase due to the increase in yield from the maturity of young fields. Meanwhile, the increased milk yields are expected to remain steady and feed cost is expected to decrease in the coming quarters due to the better management of feed and recovery of macroeconomic conditions.

Further details of the Group's performance are available on the company website. (https://www.sunshineholdings.lk/investor/financial-reports)

Shyam Sathasivam

Group Chief Executive Officer 30th May 2024 Colombo

# CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME - GROUP

	Unaudited	Audited		U	naudited	
	Period ended 31st March 2024	Period ended 31st March 2023	Change	Quarter ended 31st March 2024	Quarter ended 31st March 2023	Change
	LKR '000	LKR '000	%	LKR '000	LKR '000	%
Continuing operations						
Revenue	55,533,886	51,886,754	7	13,148,167	13,325,358	(1)
Cost of sales	(38,293,643)	(38,380,521)	-	(9,518,011)	(10,005,173)	(5)
Gross profit	17,240,243	13,506,233	28	3,630,156	3,320,185	9
Other income	355,084	154,821	129	48,286	(35,915)	(234)
Selling & distribution expenses	(5,260,705)	(3,381,440)	56	(1,425,308)	(977,577)	46
Administration expenses	(3,672,230)	(3,278,685)	12	(984,456)	(1,127,685)	(13)
Results from operating activities	8,662,392	7,000,929	24	1,268,678	1,179,008	8
Finance income	577,588	477,806	21	940	(115,356)	(101)
Finance cost	(1,168,094)	(1,463,801)	(20)	(308,402)	(243,820)	26
Net finance cost	(590,506)	(985,995)	(40)	(307,462)	(359,177)	(14)
Impairment of Goodwill	-	(354,295)	_	_	(144,295)	
Profit before tax	8,071,886	5,660,639	43	961,216	675,536	42
Income tax expense	(2,052,639)	(2,043,787)	-	(391,063)	(837,325)	(53)
Profit for the period	6,019,247	3,616,852	66	570,153	(161,789)	(452)
Profit or (loss) on discontinued operations, net of tax						
Other comprehensive income						
Equity investments at FVOCI – net change in fair value	360,558	(130,397)	-	360,558	(130,397)	-
Exchange gain/(Loss) on foreign operation translation	(3,335)	711	(569)	(2,210)	(3,473)	-
Tax on other comprehensive income	(101,089)	84,626	-	-	(133,437)	-
Remeasurement of retirement benefit liability	(24,249)	(129,252)	-	(24,249)	80,442	-
Total other comprehensive income for the period	231,885	(174,312)	(233)	334,099	(186,866)	-
Total comprehensive income for the period	6,251,132	3,442,540	82	904,252	(348,655)	(359)
Profit attributable to:						
Owners of the parent company	4,471,041	2,263,930	97	508,197	56,879	793
Non-controlling interest	1,548,206	1,352,922	14	61,955	(218,669)	(128)
Other comprehensive income attributable to:						
Owners of the parent company	238,670	(123,719)	(293)	239,796	(127,904)	(287)
Non-controlling interest	(6,785)	(50,593)	-	(6,785)	(50,593)	
Total comprehensive income for the period	6,251,132	3,442,540	82	803,163	(340,286)	(336)
Basic earnings per share	9.09	4.67		1.03	0.56	

Figures in brackets indicate deductions. n/m- not meaningful

# CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME - COMPANY

	Unaudited	Audited		ι	Jnaudited	
	Period ended 31st March 2024	Period ended 31st March 2023	Change	Quarter ended 31st March 2024	Quarter ended 31st March 2023	Change
	LKR '000	LKR '000	%	LKR '000	LKR '000	%
Revenue	2,070,290	1,381,728	50	507,664	552,505	(8)
Cost of sales	-	-	n/m	-		n/m
Gross profit	2,070,290	1,381,728	50	507,664	552,505	(8)
Other income	489,970	472,625	4	130,157	117,296	11
Administration expenses	(743,919)	(697,726)	7	(268,434)	(229,194)	17
Results from operating activities	1,816,341	1,156,627	57	369,387	440,609	(16)
Finance income	159,616	122,206	31	40,800	37,026	10
Finance cost	(1,217)	(27,759)	(96)	(45)	174	(126)
Net finance cost	158,399	94,447	68	40,755	37,200	10
Profit before tax	1,974,740	1.251.074	58	410.142	477,809	(14)
Income tax expense	17,288	(738)	(2,442)	10,601	39,297	(73)
Profit for the period	1,992,028	1,250,336	59	420,744	517,105	(19)
Other comprehensive income						
Equity investments at FVOCI – net change	360,558	(130,397)	-	-	(130,397)	-
RelaxTax	(105,565)	46,928	-	(105,565)	46,928	-
Defined benefit plan actuarial gain/(loss)	(8,673)	1,482	-	(8,673)	1,482	-
Total other comprehensive income for the period	246,320	(81,987)	-	(114,238)	(81,987)	-
Total comprehensive income for the period	2,238,348	1,168,349	92	306,506	435,118	(30)
Basic earnings per share from continuing operations	4.05	2.58		0.86	1.07	

Figures in brackets indicate deductions. n/m- not meaningful

## STATEMENT OF FINANCIAL POSITION - GROUP

As at 3 lst March 2024         As at 3 lst March 2024           LKR '000         LKR '000           ASSETS         Example 1           Non current assets         6,641,907           Intangible assets         277,903           Leasehold right to bare land         359,851           Biological assets         3,658,653           Investment property         631,212           Other investments         833,617           Deferred tax assets         420,127	t 31st March 2023 LKR '000 6,735,559 349,108 243,876 3,503,611 627,528
LKR '000	6,735,559 349,108 243,876 3,503,611
ASSETS           Non current assets         6,641,907           Property, plant and equipment         6,641,907           Intangible assets         277,903           Leasehold right to bare land         359,851           Biological assets         3,658,653           Investment property         631,212           Other investments         833,617           Deferred tax assets         420,127	6,735,559 349,108 243,876 3,503,611
Non current assets         6,641,907           Property, plant and equipment         6,641,907           Intangible assets         277,903           Leasehold right to bare land         359,851           Biological assets         3,658,653           Investment property         631,212           Other investments         833,617           Deferred tax assets         420,127	349,108 243,876 3,503,611
Property, plant and equipment         6,641,907           Intangible assets         277,903           Leasehold right to bare land         359,851           Biological assets         3,658,653           Investment property         631,212           Other investments         833,617           Deferred tax assets         420,127	349,108 243,876 3,503,611
Intangible assets         277,903           Leasehold right to bare land         359,851           Biological assets         3,658,653           Investment property         631,212           Other investments         833,617           Deferred tax assets         420,127	349,108 243,876 3,503,611
Leasehold right to bare land       359,851         Biological assets       3,658,653         Investment property       631,212         Other investments       833,617         Deferred tax assets       420,127	243,876 3,503,611
Biological assets         3,658,653           Investment property         631,212           Other investments         833,617           Deferred tax assets         420,127	3,503,611
Investment property Other investments B33,617 Deferred tax assets 420,127	
Other investments 833,617 Deferred tax assets 420,127	627.528
Deferred tax assets 420,127	
	519,017
	320,099
Goodwill on Acquisition 1,387,106	1,387,106
Total non-current assets 14,210,376	13,685,904
Current assets	
Biological assets-growing crops on bearer plants 70,867	86,126
Inventories 12,063,288	9,861,121
Other investments 1,770,256	1,084,020
Current tax assets 139,133	139,070
Trade & other receivables 9,782,520	7,892,295
Amounts due from related parties 31,749	149,443
Cash & cash equivalent 5,403,789	3,110,102
Total current assets 29,261,603	22,322,177
Total assets 43,471,979	36,008,081
EQUITY AND LIABILITIES	
Equity	
Stated capital 4,240,394	4,240,394
Reserves 430,473	191,803
Retained earnings 14,233,958	11,356,303
Equity attributable to owners of the company 18,904,825	15,788,500
Non-controlling interests 3,767,868	3,448,610
Total equity 22,672,693	19,237,110
Non-current liabilities	
Loans and borrowings	1,911,006
Employee benefits I,009,377	883,412
Refundable Deposit Received -	2,518
Deferred income and capital grants 36,726	39,084
Deferred tax I,686,737	1,404,406
Total non-current liabilities 4,408,856	4,240,426
Current liabilities	
Trade and other payables 7,617,511	6,423,945
Amounts due to related parties -	55,000
Current tax liabilities 785,681	555,160
Loans and borrowings 5,311,993	3,387,971
Bank overdraft 2,689,245	2,108,469
Total current liabilities 16,390,430	12,530,545
Total equity and liabilities 43,471,979	36,008,081
Net asset value per share (Rs.) 38.43	32.08

Figures in brackets indicate deductions.

The above figures are not audited

It is certified that the Financial Statements have been prepared in compliance with the requirements of the Companies Act No. 7 of 2007.

Group Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these financial statements. Approved and signed for and on behalf of the Board,

Chairman May 30th, 2024 Colombo Group Chief Executive Officer

## STATEMENT OF FINANCIAL POSITION - COMPANY

	Unaudited	Adjusted
	As at 31st March	As at 31st March
	2024	2023
	LKR '000	LKR '000
ASSETS		
Non-current assets		
Property, Plant and Equipment	8,652	25,523
Intangible assets	14,490	19,759
Investment in subsidiaries	7,747,698	7,248,733
Other investments	782,224	465,734
Deferred tax assets	31,602	121,249
Total non-current assets	8,584,666	7,880,998
Current assets		
Inventories	296	1,883
Current tax assets	75,566	74,195
Trade & other receivables	44,017	28,133
Amounts due from related parties	257,990	233,869
Other Short Term Investments	846,226	225,000
Cash & cash equivalent	723,291	814,025
Total current assets	1,947,386	1,377,10
Total assets	10,532,052	9,258,10
Total assets	10,332,032	7,230,10
EQUITY AND LIABILITIES		
Equity	4.240.204	4 2 40 20
Stated capital	4,240,394	4,240,394
Reserves	430,590	184,270
Retained earnings	5,572,519	4,638,236
Equity attributable to owners of the company	10,243,502	9,062,900
Non-controlling interests	-	0.040.00
Total equity	10,243,502	9,062,90
Non-current liabilities		2.476
Loans and borrowings	-	3,470
Employee benefits	190,922	141,256
Total non-current liabilities	190,922	144,72
Current liabilities		
Trade and other payables	97,345	34,158
Amounts due to related parties	282	13
Current tax liabilities	-	
Loans and borrowings		16,306
Bank overdraft	-	
Total current liabilities	97,627	50,47
Total equity and liabilities	10,532,052	9,258,10
Not accet value per chara (Rc.)	20.02	18.42
Net asset value per share (Rs.)	20.82	18.42

Figures in brackets indicate deductions.

The above figures are not audited

It is certified that the Financial Statements have been prepared in compliance with the requirements of the Companies Act No. 7 of 2007.

Group Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these financial statements. Approved and signed for and on behalf of the Board,

Chairman

Chairman May 30th, 2024 Colombo Group Chief Executive Officer

## CONDENSED STATEMENT OF CHANGES IN EQUITY - GROUP FOR THE QUARTER ENDED 31 st MARCH 2024

	Attributable to owners of the company									
In LKR '000	Stated capital	Reserve on exchange gain or loss		Fair value gain or loss reserve on AFS	Retained earnings	Total	Non- controlling interest	Tota equit		
Adjusted Balance as at 01st April 2022	1,641,715	4,224	1,258	269,079	10,510,766	12,427,042	5,347,478	17,774,52		
Total Comprehensive Income										
Profit for the year	_	-	-		2,263,930	2,263,930	1,352,922	3,616,85		
Total other comprehensive income for the year	-	711	-	(83,469)	-40,961	(123,719)	-50,593	(174,312		
Total comprehensive income for the year	-	711	-	(83,469)	2,222,969	2,140,210	1,302,329	3,442,53		
Acquisition of 2.59% of Watawala Plantation PLC shares					(291,034)	(291,034)	(170,747)	(461,781		
Acquisition of 28% in Sunshine Healthcare Lanka Limited	_	_	_	_	(736,115)	(736,115)	(1,862,564)	(2,598,679		
Acquisition of NCI	_	_	_	_	7,982	7,982	(7,982)	(2,010,011		
Share Issue to Akbar Brothers (Private) Limited	2,598,679				7,702	2,598,679	-	2,598,67		
Capital Infusion in Watawala Dairy Ltd	2,070,077				(14,778)	(14,778)	14,778	2,010,01		
WHT payment on dividend distribution from Subsidiary					(97,500)	(97,500)		(97,500		
Transactions with NCI					(1.1,000)	(11,555)	196,000	196,00		
Dividend to owners for 2021/22	_	-	-	_	(245,987)	(245,987)	(1,370,682)	(1,616,669		
	2,598,679	-	-	-	(1,377,432)	1,221,247	(3,201,196)	(1,979,949		
Balance as at 31st March 2023	4,240,394	4,935	1,258	185,609	11,356,302	15,788,499	3,448,610	19,237,11		
Total Comprehensive Income										
Profit for the year	-	-	-	-	4,471,039	4,471,039	1,548,206	6,019,24		
Total other comprehensive income for the year	-	(3,335)	242,006	-	-	238,670	(6,785)	231,88		
Total comprehensive income for the year	-	(3,335)	242,006	-	4,471,039	4,709,709	1,541,421	6,251,13		
Acquisition of NCI										
WHT payment on dividend distribution from Sunshine Healthcare Lanka Ltd										
Transactions with NCI										
Dividend paid to owners for 2022/23		_		_	(565,770)	(565,770)	_	(565,770		
Dividend paid to owners for 2023/24	_	_	_		(491,974)	(491,974)	(1,365,219)	(1,857,193		
WHT payment on dividend distribution	_	_	_	_	(438,724)	(438,724)	(46,862)	(485,586		
Lina Manufacturing (Pvt) Ltd and Lina Spiro (Pvt) Ltd Share Swap					(96,918)	(96,918)	189,918	93,00		
0 ( 1 A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	-	-	-	-	(1,593,386)	(1,593,386)	(1,222,163)	(2,815,549		
Balance as at 31st March 2024	_	1,599	243,263		14,233,958	18,904,824	3,767,868	22,672,69		

Figures in brackets indicate deductions.

## **STATEMENT OF CHANGES IN EQUITY - COMPANY**

FOR THE QUARTER ENDED 31st MARCH 2024

In LKR '000	Stated capital	Fair value gain or loss reserve on AFS	General reserve	Retained earnings	Total
Adjusted Balance as at 01st April 2022	1,641,715	264,999	1,258	3,633,886	5,541,858
Total comprehensive income for the year					
Profit for the year	-	-	-	1,250,337	1,250,337
Total other comprehensive income for the year	-	(81,987)	-	-	(81,987)
Total comprehensive income for the year	-	(81,987)	-	1,250,337	1,168,350
Issue of shares to Akbar Brothers (Private) Limited	2,598,679	-	-	-	2,598,679
Dividend to owners - 2021/22	-	-	-	(245,987)	(245,987)
Balance as at 31st March 2023	4,240,394	183,012	1,258	4,638,236	9,062,899
Total comprehensive income for the period					
Profit for the year	-	-	-	1,992,026	1,992,026
Total other comprehensive income for the year	-	246,320	-	-	246,320
Total comprehensive income for the year	-	246,320	-	1,992,026	2,238,346
Dividend to owners - 2022/23 and 2023/24		-	-	(1,057,744)	(1,057,744)
Balance as at 31st March 2024	4,240,394	429,332	1,258	5,572,519	10,243,502

Figures in brackets indicate deductions.

### 10

## **STATEMENT OF CASH FLOWS - GROUP**

	Quarter ended	Audited Year ended
	31st March 2024 LKR	31st March 2023 LKR
CASH FLOWS FROM OPERATING ACTIVITIES	LIKIK	LKK
Profit before income tax	8,071,886	5,660,638
Adjustments for;		
Interest Income	(525,313)	(477,806)
Profit on Disposal of Property, Plant & Equipment	2,221	(25,722)
Write-off of Intangible assets	-	(458)
Biological assets-growing crops on bearer plants	-	(14,455)
Impairment of Goodwill	-	354,295
Fair value changes in livestock	(29,431)	157,440
Interest Expense	980,115	1,463,801
Depreciation of Property, Plant and Equipment	771,098	787,998
Amortization of Intangible Assets	92,214	87,055
Depreciation of mature planations	179,312	196,741
Provision/(Reversal) for Bad and Doubtful Debts	318,629	175,819
Provision/ (Reversal) of impairment of inventories  Amortisation of Deferred Income	103,939	154,756
Amortization of Deferred income  Amortization of Lesehold land right	(2,358)	(2,358)
Fair value gain/loss on investments	6,352	39,989
Provision for Gratuity excluding acturial gain/loss	235,618	162.859
Rent Concession	233,618	(4,605)
Fair value gain/loss on Consumer Biological Assets	(10,558)	(10,486)
Operating profit before working capital changes	10,211,259	8,806,433
	, ,	
(Increase)/decrease in inventories	(2,306,107)	(2,262,768)
(Increase)/decrease in trade and other receivables	(2,208,854)	(1,053,650)
(Increase)/decrease in amounts due from related parties Increase/(decrease) in trade and other payables	103,693	(106,254)
Increase/(decrease) in amounts due to related parties	(55,000)	(10,728)
Cash generated from/ (used in) operations	6,938,556	5,379,176
Interest paid	(494,687)	(1,362,250)
Income tax paid	(2,226,548)	(1,944,113)
Gratuity paid	(133,626)	(66,454)
Net cash generated from / (used in) operating activities	4,083,694	2,006,359
CASH FLOWS FROM INVESTING ACTIVITIES	525.212	477.007
Interest Received (Investments)/ Disposal in Other Investments	525,313 882.237	477,806 72,714
(Investments)/ Disposal in Other Investments	(1,540,386)	(366,293)
(Investments)/ Disposal in gratuity fund	9,000	19,030
Additions to Bearer plants	(36,021)	(64,052)
Additions of live stock	(306,209)	(165,176)
Acquisition of PPE	(714,795)	(1,502,498)
Acquisition of Intangible Assets	(21,006)	(40,135)
Proceeds from Disposal of PPE	30,121	472,160
Proceeds from sales of livestock	63,122	57,870
Disposal of Shares held in Subsidiary	93,000	- (4(1.701)
Acquisition of Noncontrolling interest in Subsidiaries		(461,781)
Acquisition of Subsidiaries (net of cash)	(3,685)	(1,563,684) (13,293)
Acquisition of Investment property	( ' '	
Net cash generated from / (used in) Investing activities	(1,019,308)	(3,077,332)
CASH FLOWS FROM FINANCING ACTIVITIES		
Receipts of Interest Bearing Borrowings	4,195,897	13,702,041
Proceeds from share Issued by subsidiaries to NCI	-	196,000
Repayments of Interest Bearing Borrowings	(2,958,226)	(12,467,823)
Payment to lease creditor	(167,853)	(88,865)
Dividend Paid	(2,422,963)	(1,616,668)
Net cash from / (used in) financing activities  Net increase/(decrease) in cash and cash equivalents	(1,353,145)	<b>(275,315)</b> (1,346,288)
Cash and cash equivalents at the beginning of the period	1,001,633	2,347,210
Effect of exchange rate changes on cash and cash equivalents	(3,335)	711
Cash and cash equivalents at the end of the period	2,714,545	1,001,633
Cash and cash equivalents	F 402 700	2110102
Cash in hand & bank Bank overdraft	5,403,789 (2,689,245)	3,110,102 (2,108,469)
Daily Over all all	2,714,545	1,001,633

## **STATEMENT OF CASH FLOWS - COMPANY**

	Unaudited Year ended	Audited Year ended
	31st March 2024	31st March 2023
	LKR	LKR
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before income tax	1,974,739	1,251,075
Adjustments for;	(1-2-11-1)	(0.1.40.0)
Interest income	(159,616)	(91,626)
Interest expense	1,218	28,973
Impairment of Intercompany Loan	(10,000)	-
Impairement of Investment in Subsidiary	1,034	-
Fair value gain/ loss in quoted shares and unit trust	13,462	355
Depreciation of Property, Plant and Equipment	28,113	25,050
Amortization of Intangible Assets	-	5,269
Provision for gratuity	40,993	29,603
Operating profit before working capital changes	1,889,944	1,248,699
(Increase)/decrease in trade and other receivables	(15,883)	108,596
(Increase)/Decrease in Inventory	1,587	(1,883)
(Increase)/decrease in amounts due from related parties	(24,122)	8,463
Increase/(decrease) in trade and other payables	63,187	(64,506)
Increase/(decrease) in amounts due to related parties	269	4
Cash generated from/ (used in) operations	1,914,982	1,299,373
Interest paid	(270)	(24,914)
Income tax paid	(270)	(103,702)
Net cash generated from / (used in) operating activities	1,914,712	1,170,757
Tec cash generated from (used iii) operating activities	1,717,712	1,170,737
CASH FLOWS FROM INVESTING ACTIVITIES		
Interest received	153,359	67,152
Acquisition of non-controlling interest in subsidiary	-	-
Investments in subsidiaries	(500,000)	(1,440,000)
(Investments)/ Disposal of associates	-	-
Dividend received	-	-
Investments in Short Term Investments	-	100,000
Disposal of Subsidiary (net of cash)	-	-
Proceeds on disposal of shares held in subsidiary	-	-
(Investments)/ Disposal in Short term Investments	(574,364)	(25,000)
Acquisition of property, plant & equipment	(5,973)	(1,332)
Net cash used in investing activities	(926,978)	(1,299,180)
CASH FLOWS FROM FINANCING ACTIVITIES		
Receipts of interest bearing borrowings	-	771,000
Repayment of interest bearing borrowings	-	(771,000)
Payment of lease liabilities	(20,724)	(19,860)
Dividend paid	(1,057,744)	(245,987)
Net Cash generated from / (used in) Financing Activities	(1,078,468)	(265,847)
Net increase/(decrease) in cash and cash equivalents	(90,734)	(394,270)
Cally and early a mind on the state of the manifest	014005	1 200 205
Cash and cash equivalents at the beginning of the period	814,025	1,208,295
Cash and cash equivalents at the end of the period	723,291	814,025
Cash and cash equivalents		
	722.201	814,025
Cash in hand & bank Bank overdraft	723,291	017,023

Figures in brackets indicate deductions. The above figures are not audited

## **SEGMENTAL ANALYSIS**

FOR THE QUARTER ENDED 31ST MARCH 2024

	Investment and	Management												
	Servi	ces	Healt	hcare	A	Agri		Consumer Goods		usiness	Intrag	group	Gro	up
	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
REVENUE	3,663,602	3,526,467	27,772,530	23,924,435	8,320,903	8,768,041	19,323,519	19,010,565	25,968	35,164	(3,572,635)	-3,377,918	55,533,886	51,886,753
RESULT														
Profit from operating activities	3,406,716	3,299,610	4,298,826	2,973,222	2,660,713	2,930,745	1,873,889	1,187,746	20,281	30,055	(3,598,034)	-3,420,450	8,662,392	7,000,928
Net finance cost	181,620	90,456	(520,419)	-636,701	105,132	22,743	(340,127)	-427,755	(19,992)	-34,739	3,278	-	(590,506)	(985,996)
Share of equity accounted investee	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of Goodwill	-	-	-	-354,295	-	-	-	-	-	-	-	-	-	(354,295)
Income tax expense	8,917	-313,868	(1,249,614)	-773,402	(421,110)	-621,699	(389,709)	-236,502	(1,124)	-98,315	-	-	(2,052,639)	(2,043,786)
Profit for the year	3,597,254	3,076,199	2,528,793	1,208,824	2,344,736	2,331,789	1,144,053	523,488	(835)	(102,999)	(3,594,756)	(3,420,450)	6,019,247	3,616,851
Other comprehensive income	246,320	-81,987	(11,914)	-460	(10,700)	-82,151	8,178	-9,714	-	-	-	-	231,885	(174,312)
Total comprehensive income	3,843,574	2,994,212	2,516,879	1,208,363	2,334,036	2,249,638	1,152,231	513,775	(835)	(102,999)	(3,594,756)	(3,420,450)	6,251,129	3,442,539

#### **OTHER INFORMATION**

	Investment and Management Services		Healt	Healthcare		Agri Consumer		r Goods	Goods Rental business		Intragroup		Group	
	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR
	31st March	31st March	31st March	31st March	31st March	31st March	31st March	31st March	31st March	31st March	31st March	31st March	31st March	31st March
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
Segment assets	14,082,838	12,979,903	20,666,686	14,809,533	9,431,316	8,865,548	9,079,744	8,570,907	1,258,553	1,247,623	(11,047,159)	(10,465,436)	43,471,979	36,008,081
Equity & reserves	13,788,740	12,602,911	8,455,982	6,995,726	6,397,322	6,502,988	3,930,451	2,491,431	844,803	845,639	(10,744,607)	(10,201,586)	22,672,693	19,237,110
Total liabilities	294,099	376,992	12,210,704	7,813,807	3,033,993	2,362,560	5,149,294	6,079,476	413,748	401,984	(302,549)	(263,850)	20,799,286	16,770,971
	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR	LKR
	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023	2024	2023
Depreciation	29,430	32,850	327,656	305,221	411,783	451,228	247,823	234,696	-	-	-	-	1,016,691	1,023,994
Capital expenditure	5,914	40,757	290,026	280,567	697,593	900,361	174,229	695,134	-	-	-	-	1,167,762	1,916,818

Figures in brackets indicate deductions.

#### **NOTES TO THE ACCOUNTS**

#### I. Corporate information

Sunshine Holdings PLC (the "Company") is a Company incorporated and domiciled in Sri Lanka. The ordinary shares of the Company are listed on Colombo Stock Exchange of Sri Lanka. The address of the Company's registered office is no. 60, Dharmapala Mawatha, Colombo 03, Sri Lanka.

The Group is primarily involved in managing portfolio of investments which includes manufacturing, importing and selling of pharmaceuticals & medical devices, selling and export of branded tea, manufacturing of confectionery, fresh milk, palm oil and related products.

#### 2. Interim condensed financial statements

The Interim Condensed Financial Statements for the year ended 31st March 2024, includes the "Company" referring to Sunshine Holdings PLC as the holding Company and the "Group" comprise the Company and subsidiary companies of Sunshine Consumer Lanka Limited and its subsidiaries, Sunshine Healthcare Lanka Limited (SHL) and its subsidiaries, Sunshine Packaging Lanka Limited and its subsidiary, Sunshine Wilmar (Pvt) Ltd and its subsidiaries, Sunshine Tea (Pvt) Ltd and its subsidiaries.

The ultimate parent of the company is Lamurep Investments Limited which holds 55.18% of the issued share capital of the company as at 31st March 2024.

#### 3. Approval of financial statements

The Interim Condensed Financial Statements of the Group and the Company for the period ended 31st March 2024, were authorised for issue by the Board of Directors on 30th May 2024.

#### 4. Basis of preparation

The Interim Condensed Consolidated Financial Statements have been prepared in accordance with the Sri Lanka Accounting Standards with effect from 01 January 2014 (SLFRS/LKAS). There were no changes to the accounting policies and methods of computation since the publication of the Annual Report 2022/23. Further, these Financial Statements have been prepared in compliance with the requirement of the Sri Lanka Accounting Standard - LKAS 34 on "Interim Financial Reporting".

The Interim Condensed Consolidated Financial Statements do not include all the information and disclosures required in the Annual Financial Statements, and should be read in conjunction with the Group's annual Consolidated Financial Statements as at 31 March 2023.

Previous period figures and phrases have been rearranged wherever necessary to conform to the current presentation.

#### **5. Significant Accounting Policies**

The accounting policies applied in these interim financial statements are the same as those applied in the Group's consolidated financial statements as at and for the year ended 31 March 2023.

#### 5.1. Standards Issued but not yet Effective

A number of new standards and amendments to standards are effective for annual periods beginning after I April 2024 and early application is permitted; however the Group has not early adopted any of the forthcoming new or amended standards in preparing these condensed consolidated interim financial statements.

#### 5.2. Basis of Consolidation

Subsidiaries are those entities controlled by the Group. Control is the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. In assessing control, the Group takes in to consideration that substantive rights that give the ability to direct the activities of the subsidiaries.

The Financial Statements of the subsidiaries are included in the Consolidated Financial Statements from the date the control effectively commences until the date that control effectively ceases. Non- controlling interest is measured at the

proportionate share of the acquiree's identifiable net assets. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

#### 5.3. Use of judgements and estimates

"In preparing these interim condensed financial statements, management has made judgements and estimates that affected the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ these estimates.

The significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those described in the last annual financial statements.

#### 5.4. Property, Plant & equipment

#### Recognition and measurement

Property, plant and equipment is recorded at cost less accumulated depreciation and accumulated impairment losses if any, whilst land is measured at fair value.

#### De-recognition

The carrying amount of an item of Property, plant & equipment is de-recognised on disposal; or when no future economic benefits are expected from its use. Gains and losses on de-recognition are recognised in income statement and gains are not classified as revenue. When re-valued assets are sold, any related amount included in the revaluation reserve is transferred to Retained Earnings.

#### Depreciation

Depreciation is recognised in income statement on a straight-line basis over the estimated useful lives of each part of an item of property, plant & equipment.

#### 5.4.1 Impairment

The Board of Directors has assessed the potential impairment loss of the property, plant and equipment as at 31 March 2023. Based on the assessment, no impairment provision is required to be made in the financial statements as at the reporting date.

#### 5.5. Biological assets

The Group recognise the biological assets when, and only when, the Company controls the assets as a result of past events, it is probable that future economic benefits associated with the assets will flow to the entity and fair value or cost of the assets can be measured reliably.

#### Bearer biological assets

Tea, rubber, oil palm, cinnamon ,sundry crops and nurseries are classified as bearer biological assets. The bearer biological assets are measured at cost less accumulated depreciation and accumulated impairment losses, if any, in terms of Sri Lanka Accounting Standard LKAS 16 - Property Plant and Equipment as per the ruling issued by Institute of Chartered Accountants of Sri Lanka.

#### Consumable biological assets

Timber plantation is classified as consumable biological assets and is measured on initial recognition and at the end of each reporting period at fair value less cost to sell. Costs to sell include all costs that would be necessary to sell the assets, including transportation costs. The fair value of trees younger than five years cannot be reliably estimated and are carried at cost less impairment. The cost includes direct material, direct labour and appropriate proportion of directly attributable overheads. Gains or losses arising on initial recognition of timber plantations at fair values less costs to sell and from the change in fair values less costs of plantations at each reporting date are included in profit or loss for the period in which they arise. All costs incurred in maintaining the assets are included in Profit or Loss for the period in which they arise.

#### Livestock

Livestock is measured at their fair value less estimated point of sale costs. Changes in fair value of livestock are recognised in the income statement.

## **NOTES TO THE ACCOUNTS (Cont...)**

#### 5.6. Investment properties

Investment properties are measured initially at cost, including transaction costs. The carrying value of an investment property includes the cost of replacing part of an existing investment property, at the time that cost is incurred if the recognition criteria are met, and excludes the costs of day to- day servicing of the investment property. Subsequent to initial recognition, the investment properties are stated at fair values, which reflect market conditions at the reporting date. Gains or losses arising from changes in fair value are included in the income statement in the year in which they arise. Fair values are evaluated at least every 3 years by an accredited external, independent valuer. Investment properties are derecognised when disposed, or permanently withdrawn from use because no future economic benefits are expected. Any gains or losses on retirement or disposal are recognised in the income statement in the year of retirement or disposal.

#### 5.7 Inventories

Inventories other than produce stock and nurseries are stated at the lower of cost or net realisable value, after making due allowances for obsolete and slow moving items. The Group uses weighted average cost formula and actual cost in assigning the cost of inventories. The cost includes expenses in acquiring stocks, production and conversion cost and other costs incurred in bringing them to their existing location and condition.

#### 6. Revenue

Revenue recognition under SLFRS 15 is based on the nature and timing of satisfaction of performance obligations, including significant payment terms.

SLFRS 15 - Revenue from contracts with customers, establishes a comprehensive framework for determining whether, how much and when revenue is recognised. The Group recognises revenue when a customer obtains control of the goods or services. Judgement is used to determine the timing of transfer of control - at a point in time or over the time.

#### a) Investments

Dividend income is recognised in profit or loss on the date on which the company or its subsidiaries right to receive payment is established. This is now under the scope of SLFRS 9.

#### b) Plantation

Customers obtain the control of the produce after the customer acknowledgement at the dispatch point. Revenue is recognized point in time, at the time of dispatch after the customer acknowledgement.

#### c) Consumer

Customers obtain control of the goods sold when the goods are delivered to and have been accepted at their premises. Invoices are generated at that point in time. Revenue is recognized when a customer obtains control of the goods or services. Determining the timing of the transfer of control is at a point in time.

#### d) Healthcare

Customers obtain control of the goods sold when the goods are delivered to and have been accepted at their premises. Invoices are generated at that point in time. Revenue is recognized when a customer obtains control of the goods or services. Determining the timing of the transfer of control is at a point in time.

#### e) Sunshine Tea

This includes income of tea export to different countries. Revenue is recognised point in time, at the time of dispatch after the customer acknowledgement.

#### f) Rent income

This includes rental income earned from renting out investment property owned by the Subsidiary. Revenue is recognized over time as the rent income is recognized on a straight line basis over the term of the agreement.

#### 6.1 Disaggregation of Revenue from Contracts with Customers

The disaggregation of revenue has been provided under segmental analysis.

#### 7. Investments in subsidiaries

Quoted and unquoted investments in shares held on long term basis by the Company and Group are stated at cost less provision for diminution in value of investments.

#### 7.1. Change In NCI

Akbar Pharmaceutical Holdings (Private) Limited was amalgamated with Lina Manufacturing (Pvt) Ltd with effect from 16 March 2023. Accordingly, on the 16 March 2023 the book value of Akbar Pharmaceutical Holdings (Private) Limited was amalgamated with Lina Manufacturing (Pvt) Ltd and Akbar Pharmaceutical Holdings (Private) Limited company name has been discontinued with all operations being transacted under the name of Lina Manufacturing (Pvt) Limited.

On August 03, 2023, Lina Manufacturing Private Limited ("LMPL"), which is a subsidiary of Sunshine Healthcare Lanka Limited, became a 100% ownership of Lina Spiro (Private) Limited ("LSPL") with the acquisition of remaining Non-Controlling Interest of 49%. The consideration for this purchase was satisfied by the issuance of new ordinary shares in Lina Manufacturing (Pvt) Ltd to Celogen for a consideration of Rs.307 million. As a result of this transaction, the effective shareholding in LMPL held by the SHL diluted from 90.62% to 71.6%.

Gordon Frazer & Bosanquate Skrine company Ltd was amalgamated with Sunshine Tea (Pvt) Ltd a fully owned subsidiary of Sunshine Tea (Pvt) Ltd with effect from 27 September 2023. Accordingly, the book value of Gordon Frazer & Bosanquate Skrine company Ltd was amalgamated with Sunshine Tea (Pvt) Ltd and Sunshine Tea (Pvt) Ltd continues as the surviving entity.

International Finance Corporation (IFC), a member of the World Bank Group, has entered into an agreement on 3rd May 2024, for a proposed made an equity investment of \$ 10 million ( LKR 3,270 million) into Sunshine Healthcare Lanka Limited, the healthcare arm of Sunshine Holdings PLC. Subject to satisfaction of conditions, IFC will own approximately 14.7% stake in Sunshine Healthcare Lanka Ltd.

#### 7.2. Investment in a Subsidiary

The Company has entered into a share sale and purchase agreement with Mr Govindasamy Sathasivam, the owner of Sunshine Tea (Private) Limited ("STPL"), whereby the Company acquired Three Million Five Hundred Thousand (3,500,000) shares which amounts to 100% of the total issued shares of STPL, at a total consideration of Sri Lanka Rupees One Billion Four Hundred and Forty Million (Rs. I,440,000,000) on I April 2022.

The board of directors of SUN at the meeting held on 18 January 2024 resolved to infuse a sum of Sri Lanka Rupees Five Hundred Million (Rs. 500,000,000/-) into the capital of it's subsidiary STPL. STPL accordingly capitalized such sum of Sri Lanka Rupees Five Hundred Million (Rs. 500,000,000/-) by the issue of fully paid ordinary shares to the Company.

## **NOTES TO THE ACCOUNTS (Cont...)**

#### 8. Valuation of Financial Assets and Liabilities

#### 8.1. Accounting Classification and Fair Values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy.

			GROUP					C	COMPANY			
	Classification	Carrying		Fair v	alue		Carrying_		Fair v	alue		
31 March 2024		amount	Level I	Level 2	Level 3	Total	amount	Level I	Level 2	Level 3	Tota	
<b>Financial Assets measured</b>	at Fair value											
Investment in Unquoted Shares	Fair value through OCI	670,469	-	-	670,469	670,469	670,469	-	_	670,469	670,469	
Investment in Quoted Shares	Fair value through P&L	7,549	7,549	-	-	7,549	7,549	7,549	_	-	7,549	
Investment in UnitTrust	Fair value through P&L	1,545,256	1,545,256	-	-	1,545,256	621,226	621,226	-	-	621,226	
Investment Fund	Fair value through P&L	51,393	-	51,393	-	51,393	-	-	-	-		
		2,274,667	1,552,805	51,393	670,469	2,274,667	1,299,244	628,775	-	670,469	1,299,244	
Financial Assets not measu	red at Fair value											
Trade and other receivables **	Amortized cost	9,722,749	-	-	-	9,722,749	44,017	-	_	-	44,017	
Investment in Debentures	Amortized cost	104,206	-	-	-	104,206	104,206	-	-	-	104,206	
Short term invetsment	Amortized cost	225,000	-		-	225,000	225,000			-	225,000	
Amounts due from related parties **	* Amortized cost	45,749	-	-	-	45,749	257,990	-	_	-	257,990	
Cash & cash equivalents **	Amortized cost	5,403,789	-	-	-	5,403,789	723,291	-	_	-	723,291	
		15,547,264	-	-	-	15,547,264	1,354,504	-	-	-	1,354,504	
Financial Liabilities not me	asured at Fair value	•										
Loans and borrowings ***	Other financial liabilities	6,988,010	-		-	6,988,010	-	-		-	-	
Bank overdraft ***	Other financial liabilities	2,689,245	-		-	2,689,245	-	-		-	-	
Trade and other payables **	Other financial liabilities	7,603,511	-		-	7,603,511	97,345	-		-	97,345	
Amounts due to related parties **	Other financial liabilities	-	-		-	-	282	-		-	282	
		17,280,765	-	-	-	17,280,765	97,627	-		-	97,627	
			GROUP				COMPANY					
	Classification	Carrying		Fair v	alue		Carrying_				Fair value	
31 March 2023		amount	Level I	Level 2	Level 3	Total	amount	Level I	Level 2	Level 3	Total	
Financial Assets measured	at Fair value											
Investment in Unquoted Shares	Fair value through OCI	309,911	-	-	309,911	309,911	309,911	-	-	309,911	309,911	
Investment in Quoted Shares	Fair value through P&L	21,011	21,011	-	-	21,011	21,011	21,011	-	-	21,011	
Investment Fund	Fair value through P&L	53,283	-	53,283	-	53,283	-	-	-	-	-	
		384,205	21,011	53,283	309,911	384,205	330,922	21,011	-	309,911	330,922	
Financial Assets not measu	red at Fair value		,									
Trade and other receivables **	Amortized cost	7,892,295	-	-	-	7,892,295	28,133	-	-	-	28,133	
Investment in Debentures	Amortized cost	104,173	-	-	-	104,173	104,173	-	-	-	104,173	
Short term invetsment	Amortized cost	-	-	-	-	-	-		-	-		
Amounts due from related parties **	Amortized cost	149,443	-	-	-	149,443	233,869	-	-	-	233,869	
Cash & cash equivalents **	Amortized cost	3,110,102	-	-	-	3,110,102	814,025	-	-	-	814,025	
		11,256,013	_		-	11,256,013	1,180,200	-	-	-	1,180,200	
		11,230,013				, ,						
Financial Liabilities not me	asured at Fair value					, ,						
Financial Liabilities not mea	asured at Fair value Other financial liabilities		-	-	-	5,298,977	19,776	-	-	-	19,776	
		9			-		19,776	- -	-	-	19,776	
Loans and borrowings ***	Other financial liabilities	5,298,977	-	-		5,298,977					19,776 - 34,158	
Loans and borrowings *** Bank overdraft **	Other financial liabilities Other financial liabilities	5,298,977 2,108,469	-	-	-	5,298,977 2,108,469	-	-	-	-	-	

<sup>\*\*</sup> Classes of financial instruments that are not carried at fair value and of which carrying amounts are a reasonable approximation of fair value. This includes trade receivables, cash and cash equivalents, trade payable, other payables, amounts due to and due from related parties and bank overdraft. The carrying amounts of these financial assets and liabilities are a reasonable approximation of fair values due to their short term nature.

#### 8.2. Measurement of Fair Values

#### Financial Assets and Liabilities measured or disclosed at Fair Value

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

<sup>\*\*\*</sup> Discounted cash flows: The valuation model considers the present value of expected payments, discounted using a risk-adjusted discount rate.

## **NOTES TO THE ACCOUNTS (Cont...)**

The Group measures the fair value using the following fair value hierarchy, which reflects the significance of the inputs used in making the measurement. An analysis of the fair value measurement of financial and non-financial assets and liabilities are provided below:

An analysis of the fair value measurement of financial and non-financial assets and liabilities are provided below:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or

When available, the Group measures the fair value of an instrument using active quoted prices or dealer price quotations (assets and long positions are measured at a bid price; liabilities and short positions are measured at an ask price), without any deduction for transaction costs. A market is regarded as active if transactions for asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

 Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

This category includes instruments valued using;

- (a) quoted prices in active markets for similar instruments,
- (b) quoted prices for identical or similar instruments in markets that are considered to be less active, or
- (c) other valuation techniques in which almost all significant inputs are directly or indirectly observable from market data.
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs). This category includes all instruments for which the valuation technique includes inputs not based on observable data and the unobservable inputs have a significant effect on the instrument's valuation.

#### 8.2.a Valuation techniques and significant unobservable inputs

The following valuation techniques used in measuring Level 2 and Level 3 fair values at 31 March 2024 and 31 March 2023 for financial instruments measured at fair value in the statement of financial position, as well as the significant unobservable inputs used.

#### • Unquoted equity instruments - Discounted cash flows

The valuation model considers the present value of expected net cash flows from those investments discounted using a risk adjusted discount rate. The expected cash flows are derived based on the budgeted cash flow forecasts of those investments determined by considering the sensible probability of the forecast FBITDA.

#### • Interest rate swaps/Cross currency swaps- Swap models

The fair value is calculated as the present value of the estimated future cash flows. Estimates of future floating-rate cash flows are based on quoted swap rates, futures prices and interbank borrowing rates. Estimated cash flows are discounted using a yield curve constructed from similar sources and which reflects the relevant benchmark interbank rate used by market participants for this purpose when pricing interest rate swaps. The fair value estimate is subject to a credit risk adjustment that reflects the credit risk of the Group and of the counterparty; this is calculated based on credit spreads derived from current credit default swap or bond prices.

Those assumptions for assets categorised as Level 3 has been described under respective notes to the financial Statements as at 31 March 2024.

During the reporting period ended 31 March 2024 and 31 March 2023, there were no transfers between Level 1 and Level 2 fair value measurements

#### 8.3. Concentration on Credit Risk

The Group's concentration on Credit Risk as at 31 March 2024 remain the same as at 31 March 2023.

#### 9. Comparatives

The presentation and classification of the Financial Statements of the previous periods have been amended, where relevant, for better presentation and to be comparable with those of the current period.

#### 10. Stated capital is represented by shares in issue as given below:

No. of shares as at	31st March 2024	31st March 2023
Ordinary shares	491,973,629	491,973,629

#### II. Dividend

RS '000	Period ended	Period ended	Period ended
	31st December	31st December	31st March
	2023	2023	2023
	2023/24	2022/23	2021/22
	(Interim)	(Final)	(Interim)
Dividend (Rs)	491,974	565,770	245,987
No of ordinary shares	491,974	491,974	491,974
Dividend per share (cash)	1.00	1.15	0.50

#### 12. Commitments & contingencies

There has not been significant change in the nature of the contingent liabilities, which were disclosed in the Annual Report for the year ended 31st March 2023.

#### 13. Income tax

Tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in Statement of Profit or Loss except to the extent that it relates to a business combination, or items recognized directly in equity or in Other Comprehensive Income.

The Group has determined that interest and penalties relating to income taxes, including uncertain tax treatments, do not meet the definition of income taxes, and therefore accounted for them under LKAS 37 Provisions, Contingent Liabilities and Contingent Assets.

#### 16. Earnings per share

The earnings per share is computed on the profit attributable to ordinary shareholders after tax and non-controlling interest divided by the weighted average number of ordinary shares during the period. Further there was no dilution of ordinary shares outstanding at any time during the period. Therefore, diluted earnings per share is the same as basic earning per share.

#### 17. Net Assets per share

Net assets per share has been calculated, for all periods, based on the number of shares issued as at the reporting date.

#### 18. The interim Financial Statements are not audited.

## **SHAREHOLDER INFORMATION**

Market price per share	Year ended	Audited
	31st March 2024	Year ended
		31st March 2023
	Rs.	Rs.
Highest price	61.10	46.50
Lowest price	50.00	34.00
Last traded price	59.50	45.00

#### TWENTY (20) LARGEST SHAREHOLDERS AS AT

	31st March 20	24	31st March 2023	
S/N Name	No of Shares Held	%	No of Shares Held	%
I Lamurep Investments Limited Account No.04 & 0 I	271,454,139	55.18%	271,454,139	55.18%
2 Akbar Brothers Pvt Ltd A/C No I	49,241,855	10.01%	49,241,855	10.01%
3 Deepcar Limited	45,774,076	9.30%	45,574,076	9.26%
4 Citibank Newyork S/A Norges Bank Account 2	14,142,347	2.87%	6,971,908	1.42%
5 Ceylon Property Development Limited	10,915,876	2.22%	10,915,876	2.22%
6 Thread Capital (Private) Limited	8,846,244	1.80%	6,167,304	1.25%
7 Mr.V.Govindasamy	6,079,500	1.24%	6,079,500	1.24%
8 Rubber Investment Trust Ltd A/C No 01	3,539,729	0.72%	2,097,307	0.43%
9 Perera And Sons Bakers Pvt Limited	3,100,000	0.63%	1,500,000	0.30%
10 Invenco Capital Private Limited	2,989,777	0.61%	-	0.00%
II MR. B.W.Kundanmal	2,977,534	0.61%	2,745,922	0.56%
12 Union Assurance PLC - Universal Life Fund	2,751,454	0.56%	1,481,161	0.30%
13 Ceylon Guardian Investment Trust PLC A/C # 02	2,494,277	0.51%	1,494,277	0.30%
14 Deutsche Bank Ag As Trustee for JB Vantage value equity fund	1,831,642	0.37%	-	0.00%
15 Ceylon Investment PLC A/C # 02	1,630,000	0.33%	-	0.00%
16 J.B. Cocoshell (PVT) Limited	1,512,369	0.31%	-	0.00%
17 Jafferjee Brothers Exports (Private) Limited	1,286,787	0.26%	-	
18 Union Assurance PLC - Traditional Life Participational Fund	1,192,358	0.24%	1,481,161	0.30%
19 Employees Trust Fund	1,189,566	0.24%	-	0.00%
20 Seylan Bank PLC/JN Lanka Holdings Company (Pvt) Ltd	1,172,152	0.24%	-	-
Sub Total	434,121,682	88.24%	407,204,486	82.77%
Others	57,851,947	11.76%	84,769,143	17.23%
Total	491,973,629	100.00%	491,973,629	100.00%

#### **PUBLIC SHARE HOLDING**

	Requirement by CSE	As at 31st March 2024	Requirement by CSE	As at 31st March 2023
Option	3	3	3	3
Float adjusted market capitalization	Above Rs.5,000,000,000/-	9,176,907,095	Above Rs.5,000,000,000/-	6,940,517,971
The percentage of shares held by the public	7.5%	31.35%	7.5%	31.35%
Number of shareholders representing public holding	500	5,741	500	7,369

The number of shares held by the Board of Directors are as follows:

	As at	As at
	31st March 2024	31st March 2023
Mr.V. Govindasamy -(Deputy Chairman w.e.f. 25th January 2024)	6,079,500	6,079,500
Mr.G.Sathasivam	9,165	9,165
Mr. S.G. Sathasivam- (Group Chief Executive Officer w.e.f. 25th January 2024)	3,054	3,054
Mr. A.D.B. Talwatte	3,054	3,054

### **CORPORATE INFORMATION**

#### **Name of Company**

Sunshine Holdings PLC

#### **Legal Form**

Public Limited Liability Company (Incorporated in 1973 and listed in the Colombo Stock Exchange)

#### **Company Registration Number**

PQ13

#### **Principal Activities**

Holding Company, carrying out investment in subsidiaries

#### **Registered Office**

No. 60, Dharmapala Mawatha, Colombo 03

#### **Directors**

Mr. D. A. Cabraal

Mr.V. Govindasamy

Mr. S.G. Sathasivam

Mr. A. Talwatte

Mr. G. Sathasivam

Mr. S. Shishoo

Mr. Sudarshan Jain

Mr. S. Renganathan

Mr.Tyeabally Akbarally

Mr. Reyaz Mihular

Ms. Aruni Goonetilleke

Mr. Aruna Deepthikumara

#### **Secretaries**

Corporate Services (Private) Limited

No. 216, De Seram Place,

Colombo 10

Tel: 011 4 605 100

#### **Auditors**

KPMG

Chartered Accountants

32A, Sri Mohamed Macan Marker Mawatha,

Colombo 03

#### Lawyers

FJ&G de Saram (Attorney- at -Law)

No.216, de Saram Place

Colombo 10

Nithya Partners

Attorneys-at-Law

No. 97/A, Galle Road

Colombo 03

#### Bankers

Hatton National Bank PLC

National Development Bank PLC

MCB Bank Limited

Standard Chartered Bank Ltd.

Seylan Bank PLC

Nations Trust Bank PLC

Commercial Bank PLC

Indian Overseas Bank

Hongkong and Shanghai Banking Corporation Limited

DFCC Bank PLC

Indian Bank

#### **Credit Ratings**

The Company has been assigned a national long-term rating of 'AA+(lka)'; outlook stable by Fitch Ratings Lanka Limited